IBIO iBio Inc

iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matthew P. Greving Ph.D., its Vice President and Head of Platform Technologies and Machine Learning, will give a podium presentation titled "Enhancing Bispecific T-Cell Engager Discovery, Potency, Safety, and Developability with Machine Learning and Mammalian Display" at the 23rd annual PepTalk Conference Jan. 16-19 in San Diego, California. He will also moderate a BuzZ talk on the topic as part of the conference's "Developability of Bispecifics" program.

During the podium presentation, Dr. Greving will provide an overview of how iBio's technology stack - including epitope engineering, human-diversity antibody libraries, EngageTx™ for bispecific optimization, and ShieldTx™ for antibody masking - potentially overcomes challenges in the discovery of bispecific T-Cell Engagers (“TCE”), a promising area of research in immunotherapies for cancer. He will present data demonstrating how iBio's machine learning (ML)-driven epitope steering and mammalian-display antibody libraries efficiently discover diverse TCE arms tuned for potency, toxicity, developability, and cyno cross-reactivity. The presentation will take place Tuesday, Jan. 16 at 5:15 p.m. Pacific Time.

Before the presentation, Dr. Greving will moderate an informal, open discussion diving into topics including, but not limited to, improving discovery and productivity for bispecific TCE's immune cell arm, advances in discovering difficult tumor-antigen arm targets and epitopes, enhancing T-cell engager safety with machine-learning derived mammalian display libraries, and large-scale bispecific activity and developability screening with mammalian display. The BuzZ session will occur on Tuesday, Jan. 16, at 3:15 p.m. Pacific Time.

iBio's Drug Discovery Platform is a precision-driven and deeply integrated technology stack that aims to efficiently and consistently deliver antibody candidates against challenging targets and move them into the clinic faster. The Company uses its technology to advance candidates with partners and collaborators, and for its own proprietary pipeline.

About iBio, Inc.

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.

FORWARD LOOKING STATEMENTS

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company’s patented AI-powered tech stack, including EngageTx and ShieldTx, offering an accelerated solution to generating bispecific antibodies, the Company’s technology overcoming challenges in the discovery of bispecific T-cell engagers, the Company’s machine learning epitope steering and mammalian-display antibody library efficiently discovering diverse T-cell engager arms turned for potency, toxicity, developability, and cyno cross-reactivity, and our technology having the ability can optimize next-gen CD3-T cell engager bispecifics. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to execute its growth strategy; its ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications; acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products; competition; the Company’s ability to retain its key employees or maintain its NYSE American listing; and the other factors discussed in the Company’s filings with the SEC including the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, and the Company’s subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact:

Stephen KilmeriBio, Inc.Investor Relations(646) 274-3580skilmer@ibioinc.com

Susan ThomasiBio, Inc.Media Relations(619) 540-9195susan.thomas@ibioinc.com